Ensysce Biosciences, Inc. (ENSC) Form 8-K — Jul 15, 2026

$ENSCForm 8-KItems 5.02, 9.01Filed Jul 15, 2026, 4:15 PM ET0001493152-26-033360Original filing

Ensysce Biosciences Inc. announced that Chief Operating Officer Jeffrey Millard resigned effective July 10, 2026. The resignation was received by the company on July 10, 2026. Dr.

Price after filing

1 day: -4.8%7 days: -2.7%30 days: +19.6%

Close on the filing date to close N calendar days later (from $0.29). Historical, not a forecast.

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

Upgrade to Pro · $49/mo billed annually

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.